このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Ascendis Pharma 過去の業績

過去基準チェック /06

Ascendis Pharmaの収益は年間平均-21.7%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間11.8% 72.7%割合で増加しています。

主要情報

-21.7%

収益成長率

-17.5%

EPS成長率

Biotechs 業界の成長	-14.6%
収益成長率	72.7%
株主資本利益率	n/a
ネット・マージン	-152.4%
前回の決算情報	31 Mar 2024

Recent updates

収支内訳

Ascendis Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:A71 収益、費用、利益 ( )EUR Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	329	-502	265	378
31 Dec 23	267	-481	264	413
30 Sep 23	152	-602	257	431
30 Jun 23	119	-609	254	417
31 Mar 23	78	-569	240	403
31 Dec 22	51	-583	221	380
30 Sep 22	33	-482	213	337
30 Jun 22	19	-393	192	298
31 Mar 22	14	-446	170	291
31 Dec 21	8	-384	160	296
30 Sep 21	3	-416	132	491
30 Jun 21	5	-458	111	432
31 Mar 21	5	-418	96	349
31 Dec 20	7	-419	77	261
30 Sep 20	9	-360	73	50
30 Jun 20	8	-264	66	192
31 Mar 20	10	-228	56	140
31 Dec 19	13	-218	48	192
30 Sep 19	21	-170	40	179
30 Jun 19	19	-178	37	70
31 Mar 19	16	-142	31	161
31 Dec 18	11	-130	25	140
30 Sep 18	0	-132	21	130
30 Jun 18	1	-132	17	128
31 Mar 18	1	-140	15	110
31 Dec 17	2	-124	13	100
30 Sep 17	2	-106	13	92
30 Jun 17	3	-91	12	79
31 Mar 17	4	-73	12	70
31 Dec 16	5	-69	12	66
30 Sep 16	6	-64	12	59
30 Jun 16	6	-53	10	50
31 Mar 16	7	-55	10	49
31 Dec 15	8	-33	9	41
30 Sep 15	9	-26	8	36
30 Jun 15	10	-21	8	31
31 Mar 15	12	-8	8	23
31 Dec 14	14	-10	6	20
30 Sep 14	17	-2	4	15
30 Jun 14	20	0	3	15
31 Mar 14	20	3	3	13
31 Dec 13	20	4	2	13

質の高い収益: A71は現在利益が出ていません。

利益率の向上: A71は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: A71は利益が出ておらず、過去 5 年間で損失は年間21.7%の割合で増加しています。

成長の加速: A71の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: A71は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 3% ) と比較することは困難です。

株主資本利益率

高いROE: A71の負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Ascendis Pharma 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First quarter 2024 earnings released: €2.30 loss per share (vs €1.98 loss in 1Q 2023)

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: €8.55 loss per share (vs €10.40 loss in FY 2022)

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Third quarter 2023 earnings released: €2.88 loss per share (vs €3.03 loss in 3Q 2022)

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Recent updates

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

First quarter 2024 earnings released: €2.30 loss per share (vs €1.98 loss in 1Q 2023)

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Full year 2023 earnings released: €8.55 loss per share (vs €10.40 loss in FY 2022)

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

New major risk - Negative shareholders equity

Third quarter 2023 earnings released: €2.88 loss per share (vs €3.03 loss in 3Q 2022)

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

Full year 2022 earnings released: €10.40 loss per share (vs €7.00 loss in FY 2021)

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023

Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH

Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism

TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

Third quarter 2022 earnings released: €3.03 loss per share (vs €1.47 loss in 3Q 2021)

Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors

Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors

Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial

Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

Second quarter 2022 earnings released: €1.46 loss per share (vs €2.50 loss in 2Q 2021)

Ascendis Pharma A/S Announces Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon HGH in China Consistent

First quarter 2022 earnings released: €2.21 loss per share (vs €1.17 loss in 1Q 2021)

Ascendis Pharma A/S, Annual General Meeting, May 30, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

Ascendis Pharma A/S to Provide an Update on Two of Its Investigational Endocrinology Rare Disease Development Programs

Third quarter 2021 earnings released: €1.47 loss per share (vs €2.31 loss in 3Q 2020)

Ascendis Pharma A/S Announces Mean Bone Mineral Density Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 ß/? Clinical Program

Ascendis Pharma Announces U.S. Food and Drug Administration Approval of SKYTROFA

Second quarter 2021 earnings released: €2.50 loss per share (vs €1.97 loss in 2Q 2020)

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Notifies Information Submitted in Connection with the FDA's Ongoing Review of the Biologics License Application for Lonapegsomatropin

VISEN Pharmaceuticals Obtains the Investigational New Drug Approval from the Center for Drug Evaluation of the National Medical Products Administration for the Phase III China Clinical Trial of TransCon Parathyroid Hormone

First quarter 2021 earnings released: €1.17 loss per share (vs €1.32 loss in 1Q 2020)

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan

Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and A Well-Tolerated Safety Profile

Full year 2020 earnings released: €8.28 loss per share (vs €4.69 loss in FY 2019)

Revenue misses expectations

New 90-day low: €120

New 90-day low: €126

Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate Transcon™ TLR7/8 Agonist Clinical Program

New 90-day high: €150

Ascendis Pharma A/S Announces Michael Wolf Jensen Does Not Stand for Re-Election to Its Board

過去基準チェック /06